Form 4: Nurix Therapeutics' Chief Legal Officer, Christine Ring, Executes Stock Options and Sells Shares
SEC Form 4 Filing
Christine Ring, Chief Legal Officer of Nurix Therapeutics, exercised stock options and sold shares of common stock on September 3, 2024, according to a Form 4 filing with the SEC.
Summary
- On September 3, 2024, Christine Ring, the Chief Legal Officer of Nurix Therapeutics, Inc. (NRIX), engaged in transactions involving the company's common stock.
- Ring exercised stock options to acquire 5,760 shares at $1.86 and 3,290 shares at $9.57.
- Simultaneously, she sold 8,850 shares at a weighted average price of $24.9279 and 200 shares at $25.62.
- Following these transactions, Ring directly owns 24,592 shares of Nurix Therapeutics.
- The transactions were executed under a pre-arranged Rule 10b5-1 trading plan.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of insider trading activity. The transactions appear to be part of a pre-planned strategy (Rule 10b5-1) and don't necessarily indicate a positive or negative outlook on the company.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for insights into management's perspective on the company's stock.
Comparison to Industry Standards
- Insider trading activity is a common occurrence in publicly listed biotechnology companies like Nurix Therapeutics.
- Similar transactions are regularly reported by executives at companies such as Gilead Sciences, Amgen, and Biogen.
- The scale of these transactions is relatively small compared to the overall market capitalization of Nurix Therapeutics, suggesting it's more likely related to personal financial planning than a major shift in sentiment.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the overall effect is likely minimal given the relatively small number of shares involved.
- The transactions do not appear to have a direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 09/09/2020 | Option vested as to 1/4 of the total shares. |
| 06/28/2020 | Stock option vested as to 1/48 of the total shares monthly beginning this date. |
| 08/09/2023 | Option was fully vested. |
| 05/28/2024 | Stock option was fully vested. |
| 09/03/2024 | Date of earliest transaction: exercise of stock options and sale of shares. |
| 09/30/2029 | Expiration date of Employee Stock Option (right to buy) at $1.86. |
| 05/27/2030 | Expiration date of Employee Stock Option (right to buy) at $9.57. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.